{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:23:22Z","timestamp":1791905002540,"version":"4.3.4"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.semcancer.2018.01.008","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T22:00:46Z","timestamp":1517349646000},"page":"228-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":427,"special_numbering":"P2","title":["Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments"],"prefix":"10.1016","volume":"52","author":[{"given":"Benjamin","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3322\/caac.21384","article-title":"The global incidence of lip, oral cavity, and pharyngeal cancers by subsitein 2012","volume":"67","author":"Shield","year":"2017","journal-title":"CA. Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA. Cancer J. Clin."},{"issue":"27","key":"10.1016\/j.semcancer.2018.01.008_bib0015","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","article-title":"Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02. 02 phase III trial","volume":"28","author":"Rischin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2018.01.008_bib0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2018.01.008_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.oraloncology.2016.06.006","article-title":"Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population","volume":"60","author":"Chaturvedi","year":"2016","journal-title":"Oral Oncol."},{"issue":"36","key":"10.1016\/j.semcancer.2018.01.008_bib0035","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1200\/JCO.2013.50.3870","article-title":"Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers","volume":"31","author":"Chaturvedi","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"7417","key":"10.1016\/j.semcancer.2018.01.008_bib0040","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"N. Cancer Genome Atlas Research","year":"2012","journal-title":"Nature"},{"issue":"6046","key":"10.1016\/j.semcancer.2018.01.008_bib0045","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"issue":"6046","key":"10.1016\/j.semcancer.2018.01.008_bib0050","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.1206923","article-title":"Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1","volume":"333","author":"Agrawal","year":"2011","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.semcancer.2018.01.008_bib0055","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","article-title":"Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas","volume":"21","author":"Seiwert","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.semcancer.2018.01.008_bib0060","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/2159-8290.CD-12-0537","article-title":"Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers","volume":"3","author":"Pickering","year":"2013","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.semcancer.2018.01.008_bib0065","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1172\/JCI86862","article-title":"Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma","volume":"126","author":"Hedberg","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0070","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaoncol.2016.1790","article-title":"The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform","volume":"3","author":"Morris","year":"2016","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2018.01.008_bib0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.oraloncology.2012.09.007","article-title":"MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma","volume":"49","author":"Mroz","year":"2013","journal-title":"Oral Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0080","doi-asserted-by":"crossref","first-page":"e1001786","DOI":"10.1371\/journal.pmed.1001786","article-title":"Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas","volume":"12","author":"Mroz","year":"2015","journal-title":"PLoS Med."},{"issue":"283","key":"10.1016\/j.semcancer.2018.01.008_bib0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa1408","article-title":"Clonal status of actionable driver events and the timing of mutational processes in cancer evolution","volume":"7","author":"McGranahan","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"7536","key":"10.1016\/j.semcancer.2018.01.008_bib0090","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"N. Cancer Genome Atlas","year":"2015","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.semcancer.2018.01.008_bib0095","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","article-title":"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers","volume":"3","author":"Lui","year":"2013","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.semcancer.2018.01.008_bib0100","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/1055-9965.EPI-10-1262","article-title":"Relationship between epidermal growth factor receptor status p16(INK4A), and outcome in head and neck squamous cell carcinoma","volume":"20","author":"Young","year":"2011","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"7457","key":"10.1016\/j.semcancer.2018.01.008_bib0105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.semcancer.2018.01.008_bib0110","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.celrep.2014.05.012","article-title":"APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development","volume":"7","author":"Henderson","year":"2014","journal-title":"Cell Rep."},{"issue":"25","key":"10.1016\/j.semcancer.2018.01.008_bib0115","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1056\/NEJMoa073770","article-title":"TP53 mutations and survival in squamous-cell carcinoma of the head and neck","volume":"357","author":"Poeta","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2018.01.008_bib0120","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.28727","article-title":"Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome","volume":"135","author":"Lim","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2018.01.008_bib0125","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.oraloncology.2013.01.006","article-title":"Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome","volume":"49","author":"Young","year":"2013","journal-title":"Oral Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2018.01.008_bib0130","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1158\/1535-7163.MCT-17-0174","article-title":"Cisplatin increases sensitivity to FGFR inhibition in patient-derived xenograft models of lung squamous cell carcinoma","volume":"16","author":"Weeden","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.semcancer.2018.01.008_bib0135","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jnci\/90.11.824","article-title":"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival","volume":"90","author":"Rubin Grandis","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"24","key":"10.1016\/j.semcancer.2018.01.008_bib0140","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang","year":"2002","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.semcancer.2018.01.008_bib0145","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2018.01.008_bib0150","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"15 Suppl","key":"10.1016\/j.semcancer.2018.01.008_bib0155","doi-asserted-by":"crossref","first-page":"TPS2618","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS2618","article-title":"An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck","volume":"35","author":"Ho","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2018.01.008_bib0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.oraloncology.2016.05.008","article-title":"Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells","volume":"58","author":"Concha-Benavente","year":"2016","journal-title":"Oral Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2018.01.008_bib0165","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1535-6108(04)00112-6","article-title":"Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression","volume":"5","author":"Chung","year":"2004","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2018.01.008_bib0170","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-14-2481","article-title":"Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes","volume":"21","author":"Keck","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"29","key":"10.1016\/j.semcancer.2018.01.008_bib0175","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2015.61.1509","article-title":"Immunology and immunotherapy of head and neck cancer","volume":"33","author":"Ferris","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2018.01.008_bib0180","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1078-0432.CCR-12-2191","article-title":"The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC","volume":"19","author":"Czystowska","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.semcancer.2018.01.008_bib0185","first-page":"3137","article-title":"Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma","volume":"8","author":"Reichert","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2018.01.008_bib0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","article-title":"Overcoming barriers to effective immunotherapy: mDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer","volume":"58","author":"Davis","year":"2016","journal-title":"Oral Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1385\/IR:33:2:113","article-title":"Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance","volume":"33","author":"Ferris","year":"2005","journal-title":"Immunol. Res."},{"issue":"13","key":"10.1016\/j.semcancer.2018.01.008_bib0200","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1158\/1078-0432.CCR-05-2750","article-title":"Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer","volume":"12","author":"Ferris","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/019459988609500203","article-title":"Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis","volume":"95","author":"Wolf","year":"1986","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"3","key":"10.1016\/j.semcancer.2018.01.008_bib0210","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12105-016-0776-8","article-title":"TILs in head and neck cancer: ready for clinical implementation and why (Not)?","volume":"11","author":"De Meulenaere","year":"2016","journal-title":"Head Neck Pathol."},{"key":"10.1016\/j.semcancer.2018.01.008_bib0215","first-page":"16","article-title":"Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers","volume":"8","author":"Uppaluri","year":"2008","journal-title":"Cancer Immun."},{"issue":"3","key":"10.1016\/j.semcancer.2018.01.008_bib0220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hed.23736","article-title":"Clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers","volume":"37","author":"Wallis","year":"2015","journal-title":"Head Neck"},{"issue":"5","key":"10.1016\/j.semcancer.2018.01.008_bib0225","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00262-013-1395-9","article-title":"Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity","volume":"62","author":"Green","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0230","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/bjc.2013.639","article-title":"Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer","volume":"110","author":"Ward","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2018.01.008_bib0235","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/bjc.2015.277","article-title":"Stromal infiltration of CD8T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma","volume":"113","author":"Oguejiofor","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2018.01.008_bib0240","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.ejca.2013.03.019","article-title":"CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma","volume":"49","author":"Nordfors","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2018.01.008_bib0245","doi-asserted-by":"crossref","first-page":"e38711","DOI":"10.1371\/journal.pone.0038711","article-title":"Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer","volume":"7","author":"Nasman","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0250","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res."},{"issue":"35","key":"10.1016\/j.semcancer.2018.01.008_bib0255","doi-asserted-by":"crossref","first-page":"56781","DOI":"10.18632\/oncotarget.10788","article-title":"Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors","volume":"7","author":"Wood","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0260","doi-asserted-by":"crossref","first-page":"FSO88","DOI":"10.4155\/fso.15.88","article-title":"Differences in T-cell infiltrates and survival between HPV+ and HPV\u2212 oropharyngeal squamous cell carcinoma","volume":"2","author":"Matlung","year":"2016","journal-title":"Future Sci. OA"},{"issue":"3","key":"10.1016\/j.semcancer.2018.01.008_bib0265","first-page":"24","article-title":"Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma","volume":"5","author":"Russell","year":"2013","journal-title":"Head Neck Oncol."},{"issue":"17","key":"10.1016\/j.semcancer.2018.01.008_bib0270","doi-asserted-by":"crossref","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0275","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.pas.0000149687.90710.21","article-title":"Oral squamous cell carcinoma: histologic risk assessment but not margin status, is strongly predictive of local disease-free and overall survival","volume":"29","author":"Brandwein-Gensler","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.semcancer.2018.01.008_bib0280","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tripleo.2009.12.015","article-title":"Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma","volume":"109","author":"Watanabe","year":"2010","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"10.1016\/j.semcancer.2018.01.008_bib0285","doi-asserted-by":"crossref","first-page":"7177","DOI":"10.2147\/OTT.S113307","article-title":"The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther."},{"issue":"3","key":"10.1016\/j.semcancer.2018.01.008_bib0290","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/1078-0432.CCR-15-1543","article-title":"Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma","volume":"22","author":"Vassilakopoulou","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0295","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/bjc.2013.640","article-title":"Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer","volume":"110","author":"Balermpas","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0300","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.29683","article-title":"CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)","volume":"138","author":"Balermpas","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0305","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1078-0432.CCR-05-1886","article-title":"Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers","volume":"12","author":"Badoual","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.semcancer.2018.01.008_bib0310","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/bjc.2013.645","article-title":"Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients","volume":"109","author":"Jie","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2018.01.008_bib0315","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/0008-5472.CAN-14-2788","article-title":"CTLA-4(+) regulatory t cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis","volume":"75","author":"Jie","year":"2015","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2018.01.008_bib0320","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2326-6066.CIR-16-0333","article-title":"Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients","volume":"5","author":"Jie","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.semcancer.2018.01.008_bib0325","first-page":"3053","article-title":"Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages","volume":"29","author":"Wulff","year":"2009","journal-title":"Anticancer Res."},{"issue":"22","key":"10.1016\/j.semcancer.2018.01.008_bib0330","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1158\/1078-0432.CCR-12-1008","article-title":"Decreased NK cells in patients with head and neck cancer determined in archival DNA","volume":"18","author":"Accomando","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.semcancer.2018.01.008_bib0335","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/ijc.29962","article-title":"CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma","volume":"138","author":"Wagner","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0340","first-page":"95","article-title":"Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor","volume":"1","author":"Pak","year":"1995","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0345","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","article-title":"Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Weed","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0350","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1097-0215(19970220)74:1<69::AID-IJC12>3.0.CO;2-D","article-title":"Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells","volume":"74","author":"Young","year":"1997","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2018.01.008_bib0355","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.oraloncology.2012.09.012","article-title":"Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma","volume":"49","author":"Costa","year":"2013","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0360","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.oraloncology.2014.09.006","article-title":"Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study","volume":"51","author":"Wolf","year":"2015","journal-title":"Oral Oncol."},{"issue":"12","key":"10.1016\/j.semcancer.2018.01.008_bib0365","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1002\/cncr.20701","article-title":"Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma","volume":"101","author":"Marcus","year":"2004","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2018.01.008_bib0370","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","article-title":"Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma","volume":"73","author":"Lyford-Pike","year":"2013","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.semcancer.2018.01.008_bib0375","first-page":"6501","article-title":"B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome","year":"2003","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2018.01.008_bib0380","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.oraloncology.2011.08.007","article-title":"Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma","volume":"47","author":"Cho","year":"2011","journal-title":"Oral Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0385","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12105-012-0406-z","article-title":"B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma","volume":"7","author":"Ukpo","year":"2013","journal-title":"Head Neck Pathol."},{"issue":"11","key":"10.1016\/j.semcancer.2018.01.008_bib0390","doi-asserted-by":"crossref","first-page":"e0142656","DOI":"10.1371\/journal.pone.0142656","article-title":"High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.semcancer.2018.01.008_bib0395","doi-asserted-by":"crossref","first-page":"20902","DOI":"10.18632\/oncotarget.3939","article-title":"Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells","volume":"6","author":"Oliveira-Costa","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0400","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4143\/crt.2015.249","article-title":"Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.semcancer.2018.01.008_bib0405","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.pathol.2016.07.003","article-title":"Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype","volume":"48","author":"Satgunaseelan","year":"2016","journal-title":"Pathology"},{"issue":"11","key":"10.1016\/j.semcancer.2018.01.008_bib0410","doi-asserted-by":"crossref","first-page":"12024","DOI":"10.18632\/oncotarget.7593","article-title":"CD274\/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity","volume":"7","author":"Straub","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2018.01.008_bib0415","doi-asserted-by":"crossref","first-page":"36956","DOI":"10.1038\/srep36956","article-title":"PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"issue":"46","key":"10.1016\/j.semcancer.2018.01.008_bib0420","doi-asserted-by":"crossref","first-page":"80443","DOI":"10.18632\/oncotarget.19045","article-title":"Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer","volume":"8","author":"De Meulenaere","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2018.01.008_bib0425","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.oraloncology.2017.05.002","article-title":"Turning the tide: clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck","volume":"70","author":"De Meulenaere","year":"2017","journal-title":"Oral Oncol."},{"key":"10.1016\/j.semcancer.2018.01.008_bib0430","series-title":"A Comparative Study of PD- Diagnostic Oncology Annual Meeting","author":"Ratcliffe","year":"2016"},{"issue":"25","key":"10.1016\/j.semcancer.2018.01.008_bib0435","doi-asserted-by":"crossref","first-page":"41011","DOI":"10.18632\/oncotarget.17354","article-title":"PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients","volume":"8","author":"Goltz","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.semcancer.2018.01.008_bib0440","doi-asserted-by":"crossref","first-page":"e1329071","DOI":"10.1080\/2162402X.2017.1329071","article-title":"Preclinical immunoPET\/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma","volume":"6","author":"Kikuchi","year":"2017","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.semcancer.2018.01.008_bib0445","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.semcancer.2018.01.008_bib0450","doi-asserted-by":"crossref","first-page":"e1239005","DOI":"10.1080\/2162402X.2016.1239005","article-title":"LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma","volume":"5","author":"Deng","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2018.01.008_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oraloncology.2015.11.009","article-title":"OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment","volume":"52","author":"Bell","year":"2016","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2018.01.008_bib0460","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2018.01.008_bib0465","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdt574","article-title":"Impact of tumor HPV status on outcome in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial","volume":"25","author":"Vermorken","year":"2014","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2018.01.008_bib0470","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"issue":"32","key":"10.1016\/j.semcancer.2018.01.008_bib0475","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase ib KEYNOTE-012 expansion cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.semcancer.2018.01.008_bib0480","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum \u2013 and cetuximab-refractory head and neck cancer: results from a single-arm phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.semcancer.2018.01.008_bib0485","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.semcancer.2018.01.008_bib0490","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2018.01.008_bib0495","series-title":"Pembrolizumab (pembro) Vs Standard of Care (SOC) for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R\/M HNSCC): Phase 3 KEYNOTE-040 Trial","author":"Cohen","year":"2017"},{"key":"10.1016\/j.semcancer.2018.01.008_bib0500","first-page":"1042O","article-title":"Durvalumab for recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study","author":"Zandberg","year":"2017","journal-title":"Eur. Soc. Med. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.semcancer.2018.01.008_bib0505","first-page":"v372","article-title":"Long-term safety and clinical outcomes of atezolizumab in head and neck cancer: phase ia trial results","volume":"28","author":"Bahleda","year":"2017","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2018.01.008_bib0510","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/1078-0432.CCR-13-3473","article-title":"Lung master protocol (Lung-MAP)-A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400","volume":"21","author":"Herbst","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.semcancer.2018.01.008_bib0515","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1200\/JCO.2017.35.15_suppl.6010","article-title":"Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase I\/II results from ECHO-202\/KEYNOTE-037","volume":"35","author":"Hamid","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.semcancer.2018.01.008_bib0520","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2017.35.15_suppl.3003","article-title":"Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I\/II results of ECHO-204","volume":"35","author":"Perez","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0525","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-16-0037","article-title":"Towards precision radiotherapy for use with immune checkpoint blockers","volume":"24","author":"Vanpouille-Box","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. May 2017 (15)","key":"10.1016\/j.semcancer.2018.01.008_bib0530","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2017.35.15_suppl.6012","article-title":"Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC)","volume":"35","author":"Uppaluri","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. (13)","key":"10.1016\/j.semcancer.2018.01.008_bib0535","article-title":"Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: analyses from CheckMate 141","volume":"77","author":"Ferris","year":"2017","journal-title":"Proc. Am.. Assoc. Cancer Res."},{"issue":"8","key":"10.1016\/j.semcancer.2018.01.008_bib0540","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.semcancer.2018.01.008_bib0545","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.4287","article-title":"Towards the introduction of the \u2018Immunoscore\u2019 in the classification of malignant tumours","volume":"232","author":"Galon","year":"2014","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.semcancer.2018.01.008_bib0550","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"issue":"5","key":"10.1016\/j.semcancer.2018.01.008_bib0555","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"issue":"7","key":"10.1016\/j.semcancer.2018.01.008_bib0560","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/cncr.30449","article-title":"Immunotherapy of head and neck cancer: emerging clinical trials from a national cancer institute head and neck cancer steering committee planning meeting","volume":"123","author":"Bauman","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2018.01.008_bib0565","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/2159-8290.CD-14-1205","article-title":"Therapeutic insights from genomic studies of head and neck squamous cell carcinomas","volume":"5","author":"Hammerman","year":"2015","journal-title":"Cancer Discov."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17302560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17302560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T07:41:25Z","timestamp":1536738085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X17302560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":113,"alternative-id":["S1044579X17302560"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2018.01.008","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2018.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}